Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06465186 · ClinicalTrials.gov registry record · Phase 2

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

A Phase 2 study of Non-alcoholic Fatty Liver Disease and NAFLD, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 2
Development phase
80
Enrollment target
20
Study locations

NCT06465186 is a Phase 2 study of Non-alcoholic Fatty Liver Disease and NAFLD that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 80 participants, below the 188-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06465186, a Phase 2 study of Non-alcoholic Fatty Liver Disease and NAFLD, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
20
Study locations

Study Summary

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well people tolerate it

Conditions Studied

Non-alcoholic Fatty Liver Disease NAFLD Nonalcoholic Steatohepatitis Metabolic Dysfunction Associated Steatotic Liver Disease Metabolic Dysfunction-associated Steatohepatitis

Interventions

  • COMBINATION_PRODUCT Placebo
  • COMBINATION_PRODUCT Efinopegdutide

Study Locations (20)

Arizona

  • The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0149) - Chandler
  • Arizona Clinical Trials ( Site 0158) - Flagstaff
  • The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0120) - Peoria
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 0111) - Tucson

Florida

  • Synergy Healthcare ( Site 0118) - Bradenton
  • Homestead Associates in Research, Inc. ( Site 0139) - Homestead
  • Florida Research Institute ( Site 0116) - Lakewood Rch
  • Floridian Clinical Research, LLC ( Site 0109) - Miami Lakes

California

  • California Liver Research Institute ( Site 0113) - Pasadena
  • Acclaim Clinical Research ( Site 0137) - San Diego
  • Velocity Clinical Research, Panorama City ( Site 0124) - Van Nuys

Louisiana

  • Delta Research Partners ( Site 0160) - Bastrop
  • Louisiana Research Center ( Site 0161) - Shreveport

Maryland

  • Woodholme Gastroenterology Associates-Woodholme Gastroenterology Associates ( Site 0130) - Glen Burnie
  • Velocity Clinical Research Rockville ( Site 0143) - Rockville

Nevada

  • The Machuca Foundation ( Site 0115) - Las Vegas
  • Excel Clinical Research, LLC ( Site 0101) - Las Vegas

Colorado

  • Rocky Mountain Gastroenterology ( Site 0127) - Littleton

Georgia

  • Southeast Clinical Research Center ( Site 0119) - Dalton

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-07-12
Est. Completion 2026-08-06
Phase Phase 2

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06465186

The ClinicalTrials.gov registry entry for NCT06465186 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (57% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06465186 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Arizona, Florida, California.

Frequently Asked Questions

What is clinical trial NCT06465186 about?

NCT06465186 is a clinical study titled "A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)". Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat...

What is the current status of trial NCT06465186?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-07-12. Estimated completion is 2026-08-06.

What conditions does trial NCT06465186 study?

This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease, NAFLD, Nonalcoholic Steatohepatitis, Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis.

What interventions are being tested in trial NCT06465186?

The interventions under investigation include: Placebo (COMBINATION_PRODUCT), Efinopegdutide (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06465186?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06465186 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-alcoholic Fatty Liver Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-alcoholic Fatty Liver Disease

All registered trials for this condition

NAFLD

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.